Informe de análisis de tamaño, participación y tendencias del mercado mundial de tumores del estroma gastrointestinal: descripción general de la industria y pronóstico hasta 2031

Análisis del mercado de tumores del estroma gastrointestinal

El mercado de los tumores del estroma gastrointestinal (GIST) está experimentando un crecimiento notable, impulsado por los avances en el diagnóstico y las opciones de tratamiento. Los GIST, que son tumores raros que surgen de las células intersticiales de Cajal en el tracto gastrointestinal, han experimentado un mayor conocimiento y mejores métodos de detección, lo que permite un diagnóstico más temprano y mejores resultados para los pacientes. Los recientes avances en terapias dirigidas, en particular la aprobación de nuevos inhibidores de la tirosina quinasa, han transformado el panorama del tratamiento para los pacientes con GIST. Por ejemplo, la introducción de medicamentos como Imatinib y Sunitinib ha mejorado significativamente las tasas de supervivencia y la calidad de vida de las personas diagnosticadas con GIST avanzados. Además, se espera que la investigación en curso sobre terapias de próxima generación y tratamientos combinados mejore aún más la eficacia del tratamiento. Además, el aumento de los ensayos clínicos centrados en la medicina personalizada destaca el potencial de las terapias personalizadas basadas en el perfil genético, allanando el camino para enfoques de tratamiento innovadores. A medida que el mercado de los GIST continúa evolucionando, el énfasis en la atención multidisciplinaria y las estrategias centradas en el paciente se está volviendo cada vez más prominente, lo que promete un futuro más brillante para los pacientes que enfrentan este diagnóstico desafiante.

Tamaño del mercado de tumores del estroma gastrointestinal

El tamaño del mercado mundial de tumores del estroma gastrointestinal se valoró en USD 1.21 mil millones en 2023 y se proyecta que alcance los USD 2.02 mil millones para 2031, con una CAGR del 6,60% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología de pacientes, análisis de la cartera, análisis de precios y marco regulatorio.

Tendencias del mercado de tumores del estroma gastrointestinal

“ Aumento de la adopción de la medicina personalizada”

The gastrointestinal stromal tumor (GIST) market is experiencing notable growth driven by advancements in targeted therapies and increasing awareness of rare tumors. A key trend in this market is the rising adoption of personalized medicine, which tailors treatment based on individual genetic profiles. For instance, the approval of drugs such as QINLOCK (Ripretinib) has revolutionized treatment options for patients with advanced GIST who have not responded to multiple prior therapies. Such targeted therapy specifically addresses a broad spectrum of KIT and PDGFRα mutations, providing effective management for patients previously limited to standard treatments. Additionally, the growing emphasis on biomarker in testing is enhancing patient outcomes by ensuring that individuals receive the most appropriate therapies for their specific tumor profiles. As healthcare providers become more adept at utilizing these advanced treatment modalities, the GIST market is poised for significant expansion, offering new hope for patients battling this challenging condition.

Report Scope and Gastrointestinal Stromal Tumor Market Segmentation         

Gastrointestinal Stromal Tumor Market Definition

Gastrointestinal stromal tumor (GIST) is a type of tumor that originates in the gastrointestinal tract, most commonly in the stomach or small intestine. These tumors arise from interstitial cells of Cajal or precursor cells, which are part of the autonomic nervous system and help regulate gut motility. GISTs are characterized by the presence of specific genetic mutations, often in the KIT or PDGFRA genes, which drive their growth. GISTs are distinct from other gastrointestinal tumors due to their unique histological features and specific treatment options, primarily targeted therapies that inhibit the signaling pathways associated with the mutations.

Gastrointestinal Stromal Tumor Market Dynamics

Drivers

• Increasing Incidence of Gastrointestinal Stromal Tumor

The increasing incidence of gastrointestinal stromal tumors (GISTs) is a crucial driver for market growth, reflecting a significant rise in diagnoses over the years. According to recent studies, GISTs account for approximately 1-3% of all gastrointestinal tumors, with an estimated incidence of 10-20 cases per million people annually. This rising prevalence is largely attributed to enhanced awareness among healthcare providers and patients about GISTs and their symptoms, leading to more frequent diagnostic testing and earlier detection. As a result, the demand for effective treatment options, including targeted therapies like imatinib and sunitinib, is expected to grow significantly. Such growing recognition of GISTs as a distinct clinical entity underscores the importance of advancing treatment options, ultimately driving the gastrointestinal stromal tumor market forward.

• Growing Investment in Research and Development (R&D)

The growing investment in research and development (R&D) for gastrointestinal stromal tumor (GIST) treatments is significantly propelling market expansion. Pharmaceutical companies are increasingly allocating funds towards R&D initiatives, with an estimated global spending of around USD 145 billion in 2022, reflecting a trend toward discovering novel therapies and enhancing existing treatment modalities. Ongoing clinical trials, such as those investigating the efficacy of new targeted therapies and combination treatments, are critical in this effort; for instance, recent studies are exploring the potential of innovative agents such as Ripretinib and Avapritinib, which have shown promise in advanced GIST cases. These investments aim to secure new drug approvals and strive to expand the therapeutic landscape, ultimately leading to improved patient outcomes and prognoses. As a result, the commitment of pharmaceutical companies to advancing GIST treatment options is a key driver in the gastrointestinal stromal tumor market, fostering an environment ripe for innovation and progress in patient care.

Opportunities

• Rise in Emergence of Targeted Therapies

Emerging targeted therapies are significantly transforming the treatment landscape for gastrointestinal stromal tumor (GIST) patients, offering new hope for those who have not responded to existing treatments. Drugs like QINLOCK (Ripretinib) and Avapritinib specifically target genetic mutations, such as KIT and PDGFRA, that drive GIST growth. For instance, QINLOCK is particularly effective for patients who have undergone multiple prior therapies, providing a much-needed option for those with advanced disease. Such shift towards precision medicine enhances the effectiveness of treatment and reduces the likelihood of side effects associated with broader therapeutic approaches. The continued development and approval of such targeted therapies are poised to expand market opportunities, as they improve patient outcomes and increase demand for specialized GIST treatments.

• Increasing Awareness and Diagnosis of GIST

Increased awareness and diagnosis of gastrointestinal stromal tumors (GIST) among healthcare professionals and the general public are critical market opportunities that can lead to earlier detection and improved patient outcomes. As educational initiatives and advocacy efforts highlight the signs and symptoms of GIST, more patients are likely to seek medical attention sooner, facilitating timely interventions. For instance, awareness campaigns led by organizations such as the GIST Support International have empowered both patients and doctors to recognize the symptoms of GIST, which can often be mistaken for other gastrointestinal issues. Early diagnosis can significantly enhance treatment options, including access to targeted therapies that are more effective in the earlier stages of the disease. Consequently, this increase in awareness leads to better patient outcomes and expands the potential market for GIST treatments as more individuals are identified and treated for this rare tumor type.

Restraints/Challenges

• Limited Patient Population

The limited patient population for gastrointestinal stromal tumors (GISTs) presents a significant challenge for the market, as these tumors are classified as rare conditions. This rarity results in a smaller market size, which can deter pharmaceutical companies from investing in research and development for new therapies. For instance, GISTs account for only about 1% of all gastrointestinal tumors, leading to fewer patients participating in clinical trials and a reduced incentive for companies to pursue innovative treatments. This lack of investment can stall the development of potentially life-saving medications, leaving patients with limited options. Consequently, the challenge posed by a limited patient population hampers market growth and restricts access to new and effective therapies for those affected by GIST.

• Significant Expenses Related to Gastrointestinal Stromal Tumor Treatment

High treatment costs pose a significant challenge in the gastrointestinal stromal tumor (GIST) market, particularly for patients who lack adequate insurance coverage. Targeted therapies, such as QINLOCK (Ripretinib) and Avapritinib, while effective, can be prohibitively expensive, often costing thousands of dollars per month. For instance, patients without comprehensive health insurance may struggle to afford these medications, leading to delayed treatment or non-adherence, which can negatively impact their prognosis. This financial burden can deter patients from seeking timely interventions, exacerbating health disparities and leading to poorer health outcomes overall. Consequently, the high costs associated with GIST treatments significantly limit access to care and present a major challenge for the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Gastrointestinal Stromal Tumor Market Scope

The market is segmented on the basis of treatment type, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Chemotherapy
• Targeted Therapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Specialty Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Gastrointestinal Stromal Tumor Market Regional Analysis

The market is analyzed and market size insights and trends are provided by country, treatment type, route of administration, end users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the gastrointestinal stromal tumor (GIST) market, driven by a notable rise in the incidence of this rare cancer. The region's robust demand for targeted therapies reflects a growing preference for personalized treatment options, significantly improving patient outcomes. Additionally, the presence of advanced healthcare facilities equipped with cutting-edge technology further enhances treatment accessibility and effectiveness. This combination of factors positions North America as a dominant force in the GIST market, ensuring continued growth and innovation in therapeutic approaches.

La región de Asia y el Pacífico está preparada para el mayor crecimiento del mercado, impulsado por un aumento de la conciencia sobre los tumores del estroma gastrointestinal (GIST) y sus opciones de tratamiento asociadas. A medida que se difunden las iniciativas educativas y las campañas de atención médica, más personas reconocen la importancia del diagnóstico temprano y la intervención oportuna. Además, el rápido aumento de los ingresos disponibles entre la población está permitiendo un mayor acceso a servicios de atención médica avanzados y terapias dirigidas. Esta combinación de mayor conciencia y mejores condiciones económicas posiciona a Asia y el Pacífico como un actor importante en el mercado de GIST, impulsando la demanda de soluciones de tratamiento innovadoras.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como el análisis de la cadena de valor aguas abajo y aguas arriba, las tendencias técnicas y el análisis de las cinco fuerzas de Porter, los estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.  

Cuota de mercado de los tumores del estroma gastrointestinal

El panorama competitivo del mercado proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos, y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado.

Los líderes del mercado de tumores del estroma gastrointestinal que operan en el mercado son:

• Viatris Inc. (Estados Unidos)
• Industrias farmacéuticas Teva Ltd. (Israel)
• Sanofi (Francia)
• Pfizer Inc. (Estados Unidos)
• Novartis AG (Suiza)
• Bayer AG (Alemania)
• Lilly (Estados Unidos)
• Merck & Co., Inc. (Estados Unidos)
• Abbott (Estados Unidos)
• AbbVie Inc. (Estados Unidos)
• Merck KGaA (Alemania)
• Industrias farmacéuticas Sun Ltd. (India)
• Aurobindo Pharma (India)
• Lupino (India)
• Hikma Pharmaceuticals PLC (Reino Unido)
• Blueprint Medicines Corporation (Estados Unidos)
• NATCO Pharma Limited (India)

Últimos avances en el mercado de tumores del estroma gastrointestinal

• En agosto de 2024, Kura Oncology, Inc., una empresa biofarmacéutica en fase clínica dedicada a promover medicamentos de precisión para el tratamiento del cáncer, anunció que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) había aprobado su solicitud de nuevo fármaco en investigación (IND) para Ziftomenib. Este potente y selectivo inhibidor de la menina se está desarrollando para el tratamiento de tumores avanzados del estroma gastrointestinal (GIST)
• En septiembre de 2021, Zai Lab, una innovadora empresa biofarmacéutica en fase comercial, anunció que la Administración de Alimentos y Medicamentos de Taiwán había aprobado su solicitud de nuevo fármaco (NDA) para QINLOCK (ripretinib) para tratar a pacientes adultos con tumores del estroma gastrointestinal (GIST) avanzados que hayan sido tratados previamente con tres o más inhibidores de la quinasa, incluido el imatinib. QINLOCK se dirige específicamente a la amplia gama de mutaciones de KIT y PDGFRα asociadas con la progresión de los GIST.
• En mayo de 2020, la Administración de Alimentos y Medicamentos de los Estados Unidos aprobó los comprimidos de Qinlock (ripretinib), lo que lo convierte en el primer fármaco nuevo autorizado específicamente como tratamiento de cuarta línea para los tumores del estroma gastrointestinal (GIST) avanzados, que son tumores que se desarrollan en el tracto gastrointestinal. Qinlock está destinado a pacientes adultos que se han sometido previamente a un tratamiento con tres o más terapias con inhibidores de la quinasa, incluido el imatinib.

SKU-54246